|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MARS |
 Gene summary |
| Basic gene Info. | Gene symbol | MARS |
| Gene name | methionyl-tRNA synthetase | |
| Synonyms | METRS|MRS|MTRNS|SPG70 | |
| Cytomap | UCSC genome browser: 12q13.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004990.3, | |
| Description | cytosolic methionyl-tRNA synthetasemethionine--tRNA ligase, cytoplasmic | |
| Modification date | 20141212 | |
| dbXrefs | MIM : 156560 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000166986 | ||
| HPRD : 08864 | ||
| Vega : OTTHUMG00000169996 | ||
| Protein | UniProt: P56192 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MARS | |
| BioGPS: 4141 | ||
| Pathway | NCI Pathway Interaction Database: MARS | |
| KEGG: MARS | ||
| REACTOME: MARS | ||
| Pathway Commons: MARS | ||
| Context | iHOP: MARS | |
| ligand binding site mutation search in PubMed: MARS | ||
| UCL Cancer Institute: MARS | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for MARS |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | S31,L29 | I30N | KIRC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MARS |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | S31 | I30N | -1.5777807 | L29 | I30N | -1.5777807 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MARS from PDB |
| Top |
| Differential gene expression and gene-gene network for MARS |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MARS |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C3809651 | INFANTILE LIVER FAILURE SYNDROME 2 | 1 | GeneticVariation |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MARS |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MARS go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | I3C | 5-AMINO-2,4,6-TRIIODOISOPHTHALIC ACID | 4bjw | A | L29 S31 |
| Top |
| Conservation information for LBS of MARS |
| Multiple alignments for P56192 in multiple species |
| LBS | AA sequence | # species | Species | L29 | GRAELLISTVG | 2 | Mus musculus, Bos taurus | L29 | GRAEVLISTVG | 1 | Homo sapiens | L29 | EYASKNLKPEV | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | L29 | SAFSVKVPCEG | 1 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) | L71 | CRYFFLLSGWE | 2 | Homo sapiens, Bos taurus | L71 | CRYFFLLCGWE | 1 | Mus musculus | L71 | LRYVM------ | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | L71 | VSFLY----WK | 1 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) | L72 | RYFFLLSGWEQ | 2 | Homo sapiens, Bos taurus | L72 | RYFFLLCGWEQ | 1 | Mus musculus | L72 | RYVM------- | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | L72 | SFLY----WKQ | 1 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) | R2 | 5 | Homo sapiens, Mus musculus, Bos taurus, Saccharomyces cerevisiae (strain ATCC 204508 / S288c), Schizosaccharomyces pombe (strain 972 / ATCC 24843) | R25 | --ARGRAEVLI | 1 | Homo sapiens | R25 | --ARGRAELLI | 1 | Mus musculus | R25 | --AQGRAELLI | 1 | Bos taurus | R25 | ALALEYASKNL | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | R25 | SIAISAFSVKV | 1 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) | S31 | AELLISTVGPE | 2 | Mus musculus, Bos taurus | S31 | AEVLISTVGPE | 1 | Homo sapiens | S31 | ASKNLKPEVDN | 1 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) | S31 | FSVKVPCEGAA | 1 | Schizosaccharomyces pombe (strain 972 / ATCC 24843) |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |